T. Rowe Price Associates
EIKN

T. Rowe Price Associates’s Eikon Therapeutics EIKN Stock Holding History

T. Rowe Price Associates’s Portfolio EIKN Stock Details EIKN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.1M Buy
1,005,035
+29,201
+3% +$298K ﹤0.01% 1267
2026
Q1 		$10.3M Buy
+975,834
New +$13M ﹤0.01% 1210

Other funds holding EIKN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates's EIKN Position: Q2 2026 in Review

T. Rowe Price Associates increased its Eikon Therapeutics (EIKN) stake by 3% in Q2 2026, buying an estimated $298K and bringing the position to 1,005,035 shares worth $13.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1267.

T. Rowe Price Associates first reported a position in EIKN in Q1 2026 and has held it in 2 quarters since. 70 funds tracked by Wall St. Rank hold EIKN as of Q2 2026.

  • T. Rowe Price Associates held 1,005,035 shares of Eikon Therapeutics worth $13.1M as of Q2 2026.
  • T. Rowe Price Associates bought 29,201 Eikon Therapeutics shares in Q2 2026, an estimated $298K.
  • Eikon Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1267 holding.
  • T. Rowe Price Associates first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 70 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.